Commentary on Monoamine oxidase and its inhibitors in relation to antidepressive activity by E. Albert Zeller

Peter Riederer, Dan Rujescu

Publikation: Kapitel i bog/rapport/konference-proceedingKommentarForskningpeer review

Abstract

The review of A. Zeller reflects perfectly the status of monoamine oxidase (MAO) and its inhibitors as of 1983. He reviews especially the role of MAO and MAO-I with regard to schizophrenia and depression syndrome. Since that time, both clinical and experimental studies have led to the development of new compounds, which are more selective and safer in their clinical applications for the treatment of depression syndrome. However, the use of MAO-I for schizophrenia has not been further developed. In contrast, patients with schizophrenia nowadays are treated with antipsychotic drugs, which inhibit a variety of receptors. As such, the status reviewed by A. Zeller has been a starting point for more detailed basic research leading to development of new drugs, which are more specific, safer and more tolerable for the patients.

OriginalsprogEngelsk
TitelDiscoveries in Pharmacology : Nervous system and hormones
RedaktørerMichael Parnham, Clive Page, Jacques Bruinvels, M.J. Parnham
Vol/bind1
ForlagAcademic Press
Publikationsdato1. jan. 2023
Udgave2.
Sider137-143
Kapitel6A
ISBN (Trykt)9780323855204
ISBN (Elektronisk)9780323855198
DOI
StatusUdgivet - 1. jan. 2023

Bibliografisk note

Publisher Copyright:
© 2023 Elsevier Inc. All rights reserved.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Commentary on Monoamine oxidase and its inhibitors in relation to antidepressive activity by E. Albert Zeller'. Sammen danner de et unikt fingeraftryk.

Citationsformater